The DOMI Typhoid programme was set up to remove barriers to access to typhoid vaccines in developing countries and to accelerate the introduction of modern typhoid vaccines in countries where they are needed. DOMI Typhoid uses the Vi-Polysaccharide (Vi-PS) vaccine because it is manufactured easily and cheaply by manufacturers in developing countries, is administered in a single dose and is relatively stable. DOMI Typhoid operated at five study sites: Heichi, China; Kolkata, India; north of Jakarta, Indonesia; Karachi, Pakistan; And Hue in Vietnam. From these sites, IVI experts conducted disease surveillance, disease load studies, disease cost studies, socio-behavioural studies and vaccination demonstration projects. IVI presented the evidence collected by DOMI Typhoid in case studies to officials from each host country. Policymakers in Pakistan, Indonesia and Vietnam agreed to implement typhoid vaccination campaigns on a pilot basis. China`s results revealed an increasing incidence of Paratyphus A infections in China`s Guangxi province, leading IVI to launch its paratypical project in China. [6] The International Vaccine Institute (IVI) is an international non-profit organization established in 1997 as an initiative of the United Nations Development Programme (UNDP). We are one of the few organizations in the world that is interested in vaccines and immunization for global health.

The contracting parties to this agreement intend to create the Institute as an international organization with appropriate leadership, legal personality and international status, privileges and immunities and other conditions necessary to enable it to effectively achieve its objectives. We live in an increasingly globalized world, where emerging infectious diseases can become global health threats. The IVI also focuses on vaccines against infectious diseases, which are very concerned about health worldwide. The IVI focuses on vaccines against the world`s most depleted infectious diseases. Our goal is to make vaccines available and accessible to vulnerable populations in developing countries. The DOMI Cholera programme has attempted to develop and accelerate the use of an affordable cholera vaccine in cholera-endemic countries. DOMI Cholera operates at five study sites: Matlab, Bangladesh; north of Jakarta, Indonesia; Kolkata, India; Beira, Mozambique; And Hue in Vietnam. It is from these sites that IVI has conducted studies on the disease, economic and socio-behavioural studies and cholera vaccination campaigns.

Studies have shown strong demand for an end to the cholera vaccine and high incidence rates (3-9/1,000) in children aged 5 and under. During the IVI vaccination campaign in Beira, more than 44,000 children and adults received the internationally approved coral vaccine. In Calcutta, IVI inocculated more than 67,000 children and adults with an oral cholera vaccine produced by the Vietnamese company VaBiotech. At the beginning of DOMI Cholera, the only internationally approved dukoral was the cholera vaccine, but with $90 for the two-dose series, the vaccine was too expensive for public use in many of the poorest developing countries. VaBiotech`s cholera vaccine, originally developed by Vietnam`s National Institute of Health and Epidemiology following a technology transfer from the University of Gothenburg in Sweden, was not licensed for international use, but has shown promise as a low-cost vaccine for developing countries. As a result, the Gates IVI Foundation has made additional funds available for the creation of the Cholera Vaccine Initiative (CVI) to reformulate the VaBiotech vaccine for international use. The IVI launched the rotavirus diarrhea program to provide policy makers in developing countries with the evidence of the disease and the economic data needed to ensure the inclusion of rotavirus vaccines in their national immunization programmes. From 1999 to 2010, the Disease Surveillance and Economic Studies Program